Literature DB >> 15954078

Patterns of drug use during a 15 year period: data from a Swedish county, 1988--2002.

Louise Silwer1, Cecilia Stålsby Lundborg.   

Abstract

PURPOSE: To present and interpret drug prescription patterns, related to various groups of the population in a Swedish county, in order to estimate the prevalence of drug use in different age groups.
METHODS: Data on prescriptions, dispensed March-May 1988-2002, were combined with population statistics of Halland, a county in the south of Sweden, and analysed. Number of defined daily doses (DDD) per 100 inhabitants and day and prescriptions per 100 inhabitants and 3 months were used as indicators of drug prevalence.
RESULTS: The total drug exposure in the population of Halland nearly doubled during the 15-year period. The most frequently used drugs overall, in 2002, were psycholeptics (N05), analgesics (N02), antibacterials (J01) and sex hormones (G03). Nearly 30% of the women of 15-69 years were exposed to sex hormones. Multiplied drug prevalence among people above 60 was found for antithrombotic drugs (B01), agents acting on the renin-angiotensin system (C09), sex hormones (G03), serum lipid reducing agents (C10), antidepressants (N06) and drugs for peptic ulcer and GORD (A02B).
CONCLUSIONS: The increase in drug prescribing over the 15 years concerned both symptom-related treatments, like hormone replacement therapy, analgesics, antidepressants and drugs for acid-related disorders, as well as preventive treatments, like antithrombotics, lipid-lowering drugs and antihypertensives. The unit DDD/100 inhabitants and day gives a fairly correct measure of the percentage treated for chronic disorders. However, for short-term treatment courses and especially for drug use in children, number of prescriptions/100 inhabitants and adequate period of time, is easier to interpret. Copyright (c) 2005 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15954078     DOI: 10.1002/pds.1124

Source DB:  PubMed          Journal:  Pharmacoepidemiol Drug Saf        ISSN: 1053-8569            Impact factor:   2.890


  7 in total

1.  Views on primary prevention of cardiovascular disease--an interview study with Swedish GPs.

Authors:  Louise Silwer; Rolf Wahlström; Cecilia Stålsby Lundborg
Journal:  BMC Fam Pract       Date:  2010-06-02       Impact factor: 2.497

2.  Changes in drug prescribing to Italian community-dwelling elderly people: the EPIFARM-Elderly Project 2000-2010.

Authors:  Carlotta Franchi; Mauro Tettamanti; Luca Pasina; Codjo Djade Djignefa; Ida Fortino; Angela Bortolotti; Luca Merlino; Alessandro Nobili
Journal:  Eur J Clin Pharmacol       Date:  2014-01-08       Impact factor: 2.953

3.  Drug utilization pattern in an Omani pediatric population.

Authors:  K A Al Balushi; F Al-Sawafi; F Al-Ghafri; I Al-Zakwani
Journal:  J Basic Clin Pharm       Date:  2013-06

4.  Regional variation in prescribing for chronic conditions among an elderly population using a pharmacy claims database.

Authors:  C Naughton; K Bennett; J Feely
Journal:  Ir J Med Sci       Date:  2006 Jul-Sep       Impact factor: 1.568

5.  Discrepancies between prescribed and defined daily doses: a matter of patients or drug classes?

Authors:  Thomas Grimmsmann; Wolfgang Himmel
Journal:  Eur J Clin Pharmacol       Date:  2011-03-10       Impact factor: 2.953

6.  Drug use in children: cohort study in three European countries.

Authors:  Miriam C J M Sturkenboom; Katia M C Verhamme; Alfredo Nicolosi; Macey L Murray; Antje Neubert; Daan Caudri; Gino Picelli; Elif Fatma Sen; Carlo Giaquinto; Luigi Cantarutti; Paola Baiardi; Maria-Grazia Felisi; Adriana Ceci; Ian C K Wong
Journal:  BMJ       Date:  2008-11-24

7.  Self-reported medication in community-dwelling older adults in Germany: results from the Berlin Initiative Study.

Authors:  Nina Mielke; Dörte Huscher; Antonios Douros; Natalie Ebert; Jens Gaedeke; Markus van der Giet; Martin K Kuhlmann; Peter Martus; Elke Schaeffner
Journal:  BMC Geriatr       Date:  2020-01-21       Impact factor: 3.921

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.